ガドリニウム標的から医療用テルビウム149を量産する案

We propose a two-stage production method to overcome existing supply-constraints for the alpha-emitter $^{149\mathrm{g}}$Tb, a promising candidate for Targeted Alpha Therapy (TAT) with no existing globally scalable production pathway. Although awaiting experimental measurement of the $^{150}$Gd(p,2n)$^{149\mathrm{g}}$Tb cross section, the proposed method could produce $^{149\mathrm{g}}$Tb at clinical scale and beyond on readily available proton cyclotrons, enabled by production of the extinct but long-lived isotope $^{150}$Gd, a pure alpha emitter with a 1.79 million year half-life. Stage one generates $^{150}$Gd feedstock by irradiating natural Eu or enriched $^{151}$Eu with $\gtrsim$10 MeV protons, neutrons or photons. Stage two produces $^{149\mathrm{g}}$Tb from fabricated $^{150}$Gd targets by driving the $^{150}$Gd(p,2n)$^{149\mathrm{g}}$Tb reaction with $\gtrsim$14 MeV protons, accessible on over 700 reported cyclotrons worldwide. Fast fusion neutrons appear to offer the most scalable pathway for $^{150}$Gd production: even with a large $^{149 \mathrm{g}}$Tb dose size of 1 GBq and 40 million administered doses/yr, we estimate this would require neutrons produced by only 6.8 megawatts of steady-state deuterium-tritium power to produce the required $^{150}$Gd, far below expected capacity in the next decade. The route described here, if validated, would enable $^{149\mathrm{g}}$Tb supply at the scale needed to support clinical development of $^{149\mathrm{g}}$Tb-based TAT.

61 pages, 25 figures